Loading...
Interleukin-6 inhibitor, tocilizumab for COVID-19: Evidence review of the clinical benefit and harm
Blockman, M Cohen, K De Waal, R Gray, A Kredo, T Maartens, G Nel, J Parrish, A Rees, H Reubenson, G
Blockman, M
Cohen, K
De Waal, R
Gray, A
Kredo, T
Maartens, G
Nel, J
Parrish, A
Rees, H
Reubenson, G
Citations
Altmetric:
Abstract
Description
Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody against human IL‐6 receptor of immunoglobulin IgG1 subtype. In South Africa, is registered for use in the management rheumatoid arthritis. TCZ specifically binds soluble and membrane‐bound IL‐6 receptors (sIL‐6R and mIL‐6R) and inhibits the associated signal transduction.
Date
2020-04-15
Journal Title
Journal ISSN
Volume Title
Publisher
South African National Department of Health
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Tocilizumab, Interleukin-6 inhibitor, Antibody, immunosuppressive drug, Pharmaceutical drug, Pharmacology, Medicine, Immunology
Citation
Blockman M, Cohen K, De Waal R, Gray A, et al. Interleukin-6 inhibitor, tocilizumab for COVID-19: evidence review of the clinical benefit and harm. South African National Department of Health; 2020.
License
Attribution 3.0 United States